The International Centers for Precision Oncology Foundation (ICPO) and Munich Precision Oncology GmbH (MPO) have announced a strategic partnership to establish dedicated theranostics centers globally, starting with a pilot center in Garching, near Munich. This collaboration aims to set new standards in radiomolecular cancer treatments by leveraging cutting-edge technology and expertise from clinical, academic, and industrial partners.
The pilot center will serve as a functional demonstrator for the ICPO Foundation, showcasing advanced technologies such as total body PET/CT scanners and AI-based data analytics. ICPO will provide practical training, certified education through the ICPO Academy for Theranostics, patient workflow guidelines, and clinical protocols to ensure effective patient outcomes.
Advancing Precision Oncology
MPO GmbH, founded by entrepreneurs with expertise in radiomolecular theranostics, will combine medical, scientific, and technical expertise to deliver patient-centered precision medicine. The center will focus on developing and deploying the latest advancements in imaging, analysis, and treatment technology.
Clinical Trials and Novel Radiopharmaceuticals
One of the key goals of the partnership is to utilize the Munich pilot center and a network of ICPO theranostics centers to conduct first-in-human studies and clinical trials. This will help in advancing the development of novel radiopharmaceuticals and bridging the gap between research and patient access, ultimately leading to more precise and effective treatments for cancer patients.
Leadership Perspectives
Odile Jaume, CEO of ICPO Foundation, stated, "This partnership is a pivotal step in our mission to scale and democratize access to precision oncology, and it is a testament to the expertise and reputation of the ICPO Foundation. The Munich pilot center by MPO will demonstrate the power of collaboration, elevate the significance of radiomolecular precision oncology, and ultimately transform patient care."
Dr. Bent Witte-Reichardt, Managing Director of MPO GmbH, added, "We are excited to partner with ICPO in setting new standards in theranostics. Our aim is to establish the Munich pilot center as a model for patient-centered, state-of-the-art cancer treatment that integrates the latest innovation in imaging, analytics, and treatment. It is our ambition to create both a lighthouse, as well as a replicable model that can be implemented in other regions, ultimately contributing to the advancement of global cancer care."
